Home / Platform / CTIA
BioMedAI  ·  Agent Set 3

Clinical Trial
Intelligence Agents

CTIA will complete the BioMedAI pipeline — bringing AI intelligence to clinical trial design, site selection, patient stratification, and real-world evidence synthesis. The future of clinical execution is autonomous.

Get Notified at Launch Try DBRA Now
Coming Soon — Stage 3
2×
Projected faster clinical trial execution
~50%
Of trials fail due to patient recruitment issues CTIA targets to solve
Stage 3
Completes the full DBRA → ADDA → CTIA pipeline
DBRA — Live ADDA — In Dev CTIA — Coming Soon CTIA is Stage 3 — built to receive candidate molecules from ADDA and apply AI to the clinical development process.
The Problem CTIA Solves

Clinical Trials Are Broken at Scale

The industry's clinical execution challenges compound the already high cost of drug discovery. CTIA is being built to address these directly.

~80%
Of clinical trials fail to meet enrollment timelines
$8–15B
Average cost to bring a drug to market, driven by late-stage failures
10–15 yrs
Average drug discovery to approval timeline, with clinical phases often exceeding 7 years

Clinical trials represent the biggest bottleneck in drug development — not because the science is wrong, but because trial design, site selection, and patient recruitment rely on outdated processes.

  • Sites are selected on historical relationships, not real-time patient data
  • Protocol design doesn't leverage prior trial intelligence
  • Patient eligibility screening is manual and error-prone
  • Real-world evidence is siloed and underutilized in trial planning
  • Mid-trial adaptations happen too slowly without AI monitoring
Planned Capabilities

What CTIA Will Deliver

Site Intelligence
AI-ranked trial sites based on patient population access, investigator experience, and historical performance data.
Roadmap
Patient Stratification
Biomarker-driven eligibility screening and cohort optimization to enrich trials with the right patient subpopulations.
Roadmap
Protocol Design AI
Adaptive trial protocols generated from prior trial data, regulatory precedent, and disease-specific endpoint intelligence.
Roadmap
Real-World Evidence Synthesis
Aggregate and analyze RWE from EHR, claims, registries, and wearables to inform trial design and support regulatory submissions.
Roadmap
Regulatory Intelligence
AI-guided submission support — tracking FDA, EMA, and PMDA guidance to align trial design with regulatory expectations early.
Roadmap
Adaptive Trial Monitoring
Continuous AI monitoring of enrollment, safety signals, and efficacy indicators to enable faster mid-trial adaptations.
Roadmap
Coming Soon

Be First to Know

We'll notify you when CTIA enters beta. In the meantime, tell us your clinical trial challenge — it may shape what we build first.

Book a 30-min Discovery Call

No commitment. We're listening.

The Pipeline Starts with DBRA — Live Today

While CTIA is on the roadmap, DBRA is cutting research time by 90% right now. Start the pipeline.

Explore DBRA Full Platform